The first tranche $CYBN (-3,04%) was made as a highly speculative investment, primarily based on the following assumptions:
The psychedelics megatrend:
You are positioning yourself in the emerging market of psychedelic medicine, which has the potential to revolutionize the treatment of mental health conditions (such as major depressive disorder).
High potential for value appreciation (“ten-bagger”):
Since Cybin has not yet generated revenue (pre-revenue), the stock’s value depends almost entirely on clinical success. A positive outcome of the ongoing Phase 3 trials for the lead product CYB003 could trigger a massive revaluation of the company.
Scientific Edge:
Cybin relies on innovative, modified molecules (deuterated psychedelics), which are intended to enable improved efficacy and a shorter treatment duration—a feature that could represent a competitive advantage over approaches based solely on psilocybin.
In summary:
Investing in this company is a deliberate risk-taking decision based on the potential for a scientific breakthrough that, if successful, promises significant returns.
